Literature DB >> 23616304

Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.

Hui Cai1, Mei-Sha Chen, Zhan-Yi Sun, Yu-Fen Zhao, Horst Kunz, Yan-Mei Li.   

Abstract

The T-helper epitope peptide P30 (green in the scheme) from tetanus toxoid was used as the immunostimulant in MUC1 glycopeptide antitumor vaccines and apparently also acts as a built-in adjuvant. P30-conjugated glycopeptide vaccines containing three glycans in the immunodominant motifs PDTRP and GSTAP induced much stronger immune responses and complement dependent cytotoxicity mediated killing of tumor cells when applied in plain PBS solution without complete Freund's adjuvant.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616304     DOI: 10.1002/anie.201300390

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  26 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Recent progress in antitumoral synthetic vaccines.

Authors:  Cristina Nativi; Olivier Renaudet
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

3.  Obstacles and solutions for chemical synthesis of syndecan-3 (53-62) glycopeptides with two heparan sulfate chains.

Authors:  Weizhun Yang; Keisuke Yoshida; Bo Yang; Xuefei Huang
Journal:  Carbohydr Res       Date:  2016-10-20       Impact factor: 2.104

4.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

5.  Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.

Authors:  Tsung-Che Chang; Yoshiyuki Manabe; Keita Ito; Ryuku Yamamoto; Kazuya Kabayama; Shino Ohshima; Yoshie Kametani; Yukari Fujimoto; Chun-Cheng Lin; Koichi Fukase
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 6.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

7.  Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with R- and S-FSL-1.

Authors:  Yonghui Liu; Bocheng Yan; Zhaoyu Wang; Haomiao Zhu; Xiaona Yin; Kun Wang; Menglei Wang; Wei Zhao
Journal:  ACS Med Chem Lett       Date:  2020-06-22       Impact factor: 4.345

8.  Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Authors:  Hui Cai; Jared Orwenyo; John P Giddens; Qiang Yang; Roushu Zhang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  Cell Chem Biol       Date:  2017-10-26       Impact factor: 8.116

9.  Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition.

Authors:  Hui Cai; Rou-Shu Zhang; Jared Orwenyo; John Giddens; Qiang Yang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  J Med Chem       Date:  2018-11-08       Impact factor: 7.446

10.  Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody.

Authors:  Nuria Martínez-Sáez; Jorge Castro-López; Jessika Valero-González; David Madariaga; Ismael Compañón; Víctor J Somovilla; Míriam Salvadó; Juan L Asensio; Jesús Jiménez-Barbero; Alberto Avenoza; Jesús H Busto; Gonçalo J L Bernardes; Jesús M Peregrina; Ramón Hurtado-Guerrero; Francisco Corzana
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-26       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.